Consistent improvement in health-related quality of life with tiotropium in patients with chronic obstructive pulmonary disease: Novel and conventional responder analyses
详细信息 查看全文
- 作者：Donald P. Tashkina ; dtashkin@mednet.ucla.edu" class="auth_mail" title="E-mail the corresponding author ; Eric D. Batemanb ; eric.bateman@uct.ac.za" class="auth_mail" title="E-mail the corresponding author ; Paul Jonesc ; pjones@sgul.ac.uk" class="auth_mail" title="E-mail the corresponding author ; Valentina B. Zubekd ; valentina.zubek@boehringer-ingelheim.com" class="auth_mail" title="E-mail the corresponding author ; Norbert Metzdorfe ; norbert.metzdorf@boehringer-ingelheim.com" class="auth_mail" title="E-mail the corresponding author ; Dacheng Liud ; dacheng.liu@boehringer-ingelheim.com" class="auth_mail" title="E-mail the corresponding author ; Thomas Leonardd ; thomas.leonard@boehringer-ingelheim.com" class="auth_mail" title="E-mail the corresponding author ; Emmanuelle Clerisme-Beatyd ; emmanuelle.clerisme-beaty@boehringer-ingelheim.com" class="auth_mail" title="E-mail the corresponding author ; Robert A. Wisef ; rwise@jhmi.edu" class="auth_mail" title="E-mail the corresponding author
- 关键词：Chronic obstructive pulmonary disease (COPD) ; Clinical trials ; Health-related quality of life ; Responder and deteriorator rates ; St George's Respiratory Questionnaire (SGRQ) ; Tiotropium
- 刊名：Respiratory Medicine
- 出版年：2016
- 出版时间：November 2016
- 年：2016
- 卷：120
- 期：Complete
- 页码：91-100
- 全文大小：2238 K
文摘
- •
Novel SGRQ response analyses assessed HRQoL in COPD (tiotropium vs placebo).
- •
SGRQ total scores were consistently better for patients on tiotropium vs placebo.
- •
SGRQ score net benefit was better for tiotropium vs placebo at 6 months and 1 year.
- •
Tiotropium maintenance therapy vs placebo had long-term sustained benefit on HRQoL.
- •
These data may be a benchmark to assess benefits on HRQoL of other COPD therapies.